298 related articles for article (PubMed ID: 24569570)
1. Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma.
Grassian AR; Pagliarini R; Chiang DY
Curr Opin Gastroenterol; 2014 May; 30(3):295-302. PubMed ID: 24569570
[TBL] [Abstract][Full Text] [Related]
2. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.
Borger DR; Goyal L; Yau T; Poon RT; Ancukiewicz M; Deshpande V; Christiani DC; Liebman HM; Yang H; Kim H; Yen K; Faris JE; Iafrate AJ; Kwak EL; Clark JW; Allen JN; Blaszkowsky LS; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Bardeesy N; Straley KS; Agresta S; Schenkein DP; Ellisen LW; Ryan DP; Zhu AX
Clin Cancer Res; 2014 Apr; 20(7):1884-90. PubMed ID: 24478380
[TBL] [Abstract][Full Text] [Related]
3. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.
Wang P; Dong Q; Zhang C; Kuan PF; Liu Y; Jeck WR; Andersen JB; Jiang W; Savich GL; Tan TX; Auman JT; Hoskins JM; Misher AD; Moser CD; Yourstone SM; Kim JW; Cibulskis K; Getz G; Hunt HV; Thorgeirsson SS; Roberts LR; Ye D; Guan KL; Xiong Y; Qin LX; Chiang DY
Oncogene; 2013 Jun; 32(25):3091-100. PubMed ID: 22824796
[TBL] [Abstract][Full Text] [Related]
4. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
Borger DR; Tanabe KK; Fan KC; Lopez HU; Fantin VR; Straley KS; Schenkein DP; Hezel AF; Ancukiewicz M; Liebman HM; Kwak EL; Clark JW; Ryan DP; Deshpande V; Dias-Santagata D; Ellisen LW; Zhu AX; Iafrate AJ
Oncologist; 2012; 17(1):72-9. PubMed ID: 22180306
[TBL] [Abstract][Full Text] [Related]
5. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer.
Saha SK; Parachoniak CA; Ghanta KS; Fitamant J; Ross KN; Najem MS; Gurumurthy S; Akbay EA; Sia D; Cornella H; Miltiadous O; Walesky C; Deshpande V; Zhu AX; Hezel AF; Yen KE; Straley KS; Travins J; Popovici-Muller J; Gliser C; Ferrone CR; Apte U; Llovet JM; Wong KK; Ramaswamy S; Bardeesy N
Nature; 2014 Sep; 513(7516):110-4. PubMed ID: 25043045
[TBL] [Abstract][Full Text] [Related]
6. Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.
Delahousse J; Verlingue L; Broutin S; Legoupil C; Touat M; Doucet L; Ammari S; Lacroix L; Ducreux M; Scoazec JY; Malka D; Paci A; Hollebecque A
Eur J Cancer; 2018 Feb; 90():83-91. PubMed ID: 29274619
[TBL] [Abstract][Full Text] [Related]
7. Mutation of
Su L; Zhang X; Zheng L; Wang M; Zhu Z; Li P
Front Endocrinol (Lausanne); 2020; 11():189. PubMed ID: 32373065
[No Abstract] [Full Text] [Related]
8. Intrahepatic cholangiocarcinomas with IDH1/2 mutation-associated hypermethylation at selective genes and their clinicopathological features.
Lee K; Song YS; Shin Y; Wen X; Kim Y; Cho NY; Bae JM; Kang GH
Sci Rep; 2020 Sep; 10(1):15820. PubMed ID: 32978444
[TBL] [Abstract][Full Text] [Related]
9. IDH mutations in liver cell plasticity and biliary cancer.
Saha SK; Parachoniak CA; Bardeesy N
Cell Cycle; 2014; 13(20):3176-82. PubMed ID: 25485496
[TBL] [Abstract][Full Text] [Related]
10. Circulating Oncometabolite 2-hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (IDH1/2) Mutant Cholangiocarcinoma.
Lee CL; O'Kane GM; Mason WP; Zhang WJ; Spiliopoulou P; Hansen AR; Grant RC; Knox JJ; Stockley TL; Zadeh G; Chen EX
Mol Cancer Ther; 2024 Mar; 23(3):394-399. PubMed ID: 38015561
[TBL] [Abstract][Full Text] [Related]
11. Biology of IDH mutant cholangiocarcinoma.
Wu MJ; Shi L; Merritt J; Zhu AX; Bardeesy N
Hepatology; 2022 May; 75(5):1322-1337. PubMed ID: 35226770
[TBL] [Abstract][Full Text] [Related]
12. Platinum Sensitivity in
Doroshow DB; Wei W; Mehrotra M; Sia D; Eder JP; Bindra R; Houldsworth J; LoRusso P; Walther Z
Cancer Invest; 2023 Sep; 41(7):646-655. PubMed ID: 37505929
[TBL] [Abstract][Full Text] [Related]
13. Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study.
Niger M; Nichetti F; Casadei-Gardini A; Rizzato MD; Pircher C; Bini M; Franza A; Rimini M; Burgio V; Sposetti C; Fornaro L; Rapposelli IG; D'Amico FE; Aprile G; Vivaldi C; Frassineti GL; Milione M; Leoncini G; Cappetta A; Vasile E; Fassan M; Morano F; Perrone F; Tamborini E; Pruneri G; Lonardi S; Mazzaferro V; Pietrantonio F; Di Bartolomeo M; de Braud F
Int J Cancer; 2022 Oct; 151(8):1310-1320. PubMed ID: 35723131
[TBL] [Abstract][Full Text] [Related]
14. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma.
Kipp BR; Voss JS; Kerr SE; Barr Fritcher EG; Graham RP; Zhang L; Highsmith WE; Zhang J; Roberts LR; Gores GJ; Halling KC
Hum Pathol; 2012 Oct; 43(10):1552-8. PubMed ID: 22503487
[TBL] [Abstract][Full Text] [Related]
15. Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions.
Voss JS; Holtegaard LM; Kerr SE; Fritcher EG; Roberts LR; Gores GJ; Zhang J; Highsmith WE; Halling KC; Kipp BR
Hum Pathol; 2013 Jul; 44(7):1216-22. PubMed ID: 23391413
[TBL] [Abstract][Full Text] [Related]
16. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.
Goyal L; Govindan A; Sheth RA; Nardi V; Blaszkowsky LS; Faris JE; Clark JW; Ryan DP; Kwak EL; Allen JN; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Chong DQ; Deshpande V; Borger DR; Iafrate AJ; Bardeesy N; Zheng H; Zhu AX
Oncologist; 2015 Sep; 20(9):1019-27. PubMed ID: 26245674
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemistry using monoclonal antibody MsMab-2 is useful to detect IDH1 R132L in intrahepatic cholangiocarcinoma.
Hayashi A; Misumi K; Shibahara J; Kokudo N; Kato Y; Fukayama M
Pathol Int; 2016 Oct; 66(10):578-582. PubMed ID: 27595804
[TBL] [Abstract][Full Text] [Related]
18. Methylation profiles of multiple CpG island loci in extrahepatic cholangiocarcinoma versus those of intrahepatic cholangiocarcinomas.
Kim BH; Cho NY; Choi M; Lee S; Jang JJ; Kang GH
Arch Pathol Lab Med; 2007 Jun; 131(6):923-30. PubMed ID: 17550320
[TBL] [Abstract][Full Text] [Related]
19. Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes.
Wintheiser G; Zemla T; Shi Q; Tran N; Prasai K; Tella SH; Mody K; Ahn D; Borad M; Bekaii-Saab T; Mahipal A
JCO Precis Oncol; 2022 Jan; 6():e2100156. PubMed ID: 35005992
[TBL] [Abstract][Full Text] [Related]
20. Distinct histomorphological features are associated with IDH1 mutation in intrahepatic cholangiocarcinoma.
Wang T; Drill E; Vakiani E; Pak LM; Boerner T; Askan G; Schvartzman JM; Simpson AL; Jarnagin WR; Sigel CS
Hum Pathol; 2019 Sep; 91():19-25. PubMed ID: 31121195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
